<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02091362</url>
  </required_header>
  <id_info>
    <org_study_id>15261</org_study_id>
    <secondary_id>I1R-MC-GLDI</secondary_id>
    <secondary_id>2013-003834-33</secondary_id>
    <nct_id>NCT02091362</nct_id>
  </id_info>
  <brief_title>A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus</brief_title>
  <official_title>The Effect of LY2409021 on Blood Pressure and Pulse Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the trial is to determine the effect of a study drug known as LY2409021
      on blood pressure and pulse rate in participants with type 2 diabetes mellitus (T2DM) when
      compared to placebo. The study has two periods. Each participant will receive LY2409021 or
      placebo in each period. At least 4 weeks will pass between periods. The study will last about
      23 weeks for each participant. Participants may remain on stable dose metformin, as
      prescribed by their personal physician.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to 6 Weeks in Mean 24-Hour Systolic Blood Pressure</measure>
    <time_frame>Baseline, 6 Weeks</time_frame>
    <description>Systolic blood pressure obtained from Ambulatory Blood Pressure Monitoring (ABPM).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 6 Weeks in Mean 24-Hour Diastolic Blood Pressure</measure>
    <time_frame>Baseline, 6 Weeks</time_frame>
    <description>Diastolic blood pressure obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 6 Weeks in Mean 24-Hour, Daytime, and Nighttime Peripheral Pulse Rate</measure>
    <time_frame>Baseline, 6 Weeks</time_frame>
    <description>Pulse rate obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 6 Weeks in Mean 24-Hour, Daytime, and Nighttime Pulse Pressures</measure>
    <time_frame>Baseline, 6 Weeks</time_frame>
    <description>Pulse Pressures obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 6 Weeks in Mean 24-Hour, Daytime, and Nighttime Mean Arterial Pressures (MAP)</measure>
    <time_frame>Baseline, 6 Weeks</time_frame>
    <description>Mean Arterial Pressures obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline, 6 Weeks</time_frame>
    <description>LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Pharmacokinetics: Apparent Clearance of LY2409021</measure>
    <time_frame>Days 7, 21, 42, 70, 77, 91, 112, 140; 15 minute Predose and Days 7 and 77: 1 hour Postdose.</time_frame>
    <description>Population pharmacokinetic parameter apparent clearance (CL/F) is the apparent volume of the body fluid cleared of the drug per unit of time and was estimated by modeling of LY2409021 plasma concentration data from all LY2409021 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Pharmacokinetics: Apparent Volume of Distribution of LY2409021</measure>
    <time_frame>Days 7, 21, 42, 70, 77, 91, 112, 140; Predose and Days 7 and 77: 1 hour Postdose.</time_frame>
    <description>Population pharmacokinetic parameter, apparent volume of distribution (V/F) is a theoretical volume that a drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma. Apparent volume of distribution (V/F) was estimated by modeling of LY2409021 plasma concentration data from all LY2409021 groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2409021</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY2409021</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Administered as background therapy.</description>
    <arm_group_label>LY2409021</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have type 2 diabetes mellitus (according to the World Health Organization diagnostic
             criteria) and use diet and exercise alone or in combination with a stable dose of
             metformin ( &gt;/=1000 mg/day [or &lt;1000 mg, if documented intolerance to 1000 mg or
             higher dosages] immediate-release metformin or extended-release metformin for at least
             2 months before screening).

          -  Have glycated hemoglobin (HbA1c) values &gt;/=6.5% and &lt;/=8.5%, as determined by the
             central laboratory at screening.

          -  Have mean blood pressures &gt;90/60 millimeters of mercury (mm Hg) and &lt;140/90 mm Hg at
             screening.

          -  If being treated for hypertension, are taking 3 or fewer antihypertensive medications
             and have been taking stable doses of the same medications for at least 1 month before
             screening.

          -  Stable body weights (±5%) for &gt;/=3 months before screening.

          -  Body mass indexes &gt;/=20 kilograms/meters squared (kg/m²) and &lt;40 kg/m².

          -  In the investigator's opinion, are well motivated, capable, and willing to:

               -  Reliably administer the oral study drug once daily;

               -  Maintain a study diary;

               -  Perform self-monitored blood glucose testing; and

               -  Wear an ambulatory blood pressure monitoring device for at least 24 hours (on
                  multiple occasions).

          -  Are women not of child-bearing potential due to:

               -  Surgical sterilization, hysterectomy, or bilateral oophorectomy (at least 6 weeks
                  postsurgery) or tubal ligation (confirmed by medical history); or

               -  Menopause. Women with an intact uterus are deemed menopausal if they have a
                  cessation of menses for at least 1 year with follicle stimulating hormone &gt;40
                  milli-international units per milliliter (mIU/mL), are not taking hormones or
                  oral contraceptives within 1 year, and are otherwise healthy.

          -  Males who are sexually active and/or have partners of child-bearing age must use
             reliable methods of birth control during the study and until 3 months after the last
             doses of study medication. These requirements do not apply if a participant or his
             partner has been surgically sterilized or is not between menarche and 1 year
             postmenopausal.

        Exclusion Criteria:

          -  Have severe gastrointestinal disease that may significantly affect gastric emptying or
             motility.

          -  Previous histories or active diagnoses of pancreatitis.

          -  Acute or chronic hepatitis, signs or symptoms of any other liver disease, or alanine
             aminotransferase (ALT) level greater than 2.5 times the upper limit of normal (ULN).

          -  Elevated total bilirubin (greater than 2 times ULN), clinically suspicious signs or
             symptoms of cirrhosis or history of cirrhosis.

          -  Mean resting pulse rate (PR) less than 60 beats per minute (bpm) or greater than 100
             bpm.

          -  Current diagnosis or personal history of neuroendocrine tumors, family history of any
             type of multiple endocrine neoplasia, or Von Hippel-Lindau disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Investigators, Inc.</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berma Research</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Coast Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Group, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar-Crosse Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute for Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L-Marc Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Research Associates</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alzohaili Medical Consultants</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Research</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <zip>08611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Research</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Holesov</city>
        <zip>76901</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Krnov</city>
        <zip>79401</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pardubice</city>
        <zip>53002</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Prague</city>
        <zip>14059</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Coatzacoalcos</city>
        <zip>96400</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guadalajara</city>
        <zip>44130</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monterrey</city>
        <zip>64620</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gdansk</city>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lodz</city>
        <zip>90-242</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lublin</city>
        <zip>20-538</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poznan</city>
        <zip>61-853</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szczecin</city>
        <zip>70-506</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manati Center for Clinical Research Inc</name>
      <address>
        <city>Manati</city>
        <zip>00674</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Medico</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>March 18, 2014</study_first_submitted>
  <study_first_submitted_qc>March 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2014</study_first_posted>
  <results_first_submitted>June 6, 2018</results_first_submitted>
  <results_first_submitted_qc>July 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 19, 2018</results_first_posted>
  <disposition_first_submitted>May 8, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>May 8, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 25, 2015</disposition_first_posted>
  <last_update_submitted>July 17, 2018</last_update_submitted>
  <last_update_submitted_qc>July 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LY2409021/Placebo</title>
          <description>Period 1: Single daily dose of 20 milligrams (mg) LY2409021 administered orally for 6 weeks; Wash-out: 4 weeks; Period 2: Single daily dose of placebo administered orally for 6 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo/LY2409021</title>
          <description>Period 1: Single daily dose of placebo administered orally for 6 weeks; Wash-out: 4 weeks; Period 2: Single daily dose of 20 milligrams (mg) LY2409021 administered orally for 6 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Wash-out</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LY2409021 20 mg</title>
          <description>Period 1: Single daily dose of 20 mg LY2409021 administered orally for 6 Weeks; Wash-out: 4 weeks; Period 2: Single daily dose of placebo administered orally for 6 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Period 1: Single daily dose of placebo administered orally for 6 weeks; Wash-out: 4 weeks; Period 2: Single daily dose of 20 mg Ly2409021 administered orally for 6 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="133"/>
            <count group_id="B2" value="137"/>
            <count group_id="B3" value="270"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="8.9"/>
                    <measurement group_id="B2" value="57.2" spread="8.9"/>
                    <measurement group_id="B3" value="57.7" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis of Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c (HBA1c)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>≥ 7.5 %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 7.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to 6 Weeks in Mean 24-Hour Systolic Blood Pressure</title>
        <description>Systolic blood pressure obtained from Ambulatory Blood Pressure Monitoring (ABPM).</description>
        <time_frame>Baseline, 6 Weeks</time_frame>
        <population>Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2409021 20 mg</title>
            <description>Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 6 Weeks in Mean 24-Hour Systolic Blood Pressure</title>
          <description>Systolic blood pressure obtained from Ambulatory Blood Pressure Monitoring (ABPM).</description>
          <population>Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" lower_limit="1.62" upper_limit="3.95"/>
                    <measurement group_id="O2" value="0.53" lower_limit="-0.70" upper_limit="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>3.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 6 Weeks in Mean 24-Hour Diastolic Blood Pressure</title>
        <description>Diastolic blood pressure obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.</description>
        <time_frame>Baseline, 6 Weeks</time_frame>
        <population>Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2409021 20 mg</title>
            <description>Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 6 Weeks in Mean 24-Hour Diastolic Blood Pressure</title>
          <description>Diastolic blood pressure obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.</description>
          <population>Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" lower_limit="0.61" upper_limit="2.14"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.76" upper_limit="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>2.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 6 Weeks in Mean 24-Hour, Daytime, and Nighttime Peripheral Pulse Rate</title>
        <description>Pulse rate obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.</description>
        <time_frame>Baseline, 6 Weeks</time_frame>
        <population>Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2409021 20 mg</title>
            <description>Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 6 Weeks in Mean 24-Hour, Daytime, and Nighttime Peripheral Pulse Rate</title>
          <description>Pulse rate obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.</description>
          <population>Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.</population>
          <units>beats/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Hour Pulse Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" lower_limit="-0.46" upper_limit="1.37"/>
                    <measurement group_id="O2" value="0.43" lower_limit="-0.53" upper_limit="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Daytime Pulse Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" lower_limit="-0.26" upper_limit="1.75"/>
                    <measurement group_id="O2" value="0.56" lower_limit="-0.48" upper_limit="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Nighttime Pulse Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" lower_limit="-1.35" upper_limit="0.57"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-1.03" upper_limit="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 6 Weeks in Mean 24-Hour, Daytime, and Nighttime Pulse Pressures</title>
        <description>Pulse Pressures obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.</description>
        <time_frame>Baseline, 6 Weeks</time_frame>
        <population>Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2409021 20 mg</title>
            <description>Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 6 Weeks in Mean 24-Hour, Daytime, and Nighttime Pulse Pressures</title>
          <description>Pulse Pressures obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.</description>
          <population>Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24-Hour Pulse Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" lower_limit="0.76" upper_limit="2.25"/>
                    <measurement group_id="O2" value="0.62" lower_limit="-0.13" upper_limit="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daytime Pulse Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" lower_limit="0.68" upper_limit="2.29"/>
                    <measurement group_id="O2" value="0.54" lower_limit="-0.29" upper_limit="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nighttime Pulse Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" lower_limit="0.69" upper_limit="2.32"/>
                    <measurement group_id="O2" value="0.80" lower_limit="0.00" upper_limit="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 6 Weeks in Mean 24-Hour, Daytime, and Nighttime Mean Arterial Pressures (MAP)</title>
        <description>Mean Arterial Pressures obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.</description>
        <time_frame>Baseline, 6 Weeks</time_frame>
        <population>Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2409021 20 mg</title>
            <description>Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 6 Weeks in Mean 24-Hour, Daytime, and Nighttime Mean Arterial Pressures (MAP)</title>
          <description>Mean Arterial Pressures obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.</description>
          <population>Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Hour MAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" lower_limit="0.99" upper_limit="2.68"/>
                    <measurement group_id="O2" value="0.17" lower_limit="-0.71" upper_limit="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daytime MAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" lower_limit="1.14" upper_limit="2.94"/>
                    <measurement group_id="O2" value="0.08" lower_limit="-0.86" upper_limit="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nighttime MAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" lower_limit="0.33" upper_limit="2.29"/>
                    <measurement group_id="O2" value="0.33" lower_limit="-0.68" upper_limit="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin A1c (HbA1c)</title>
        <description>LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.</description>
        <time_frame>Baseline, 6 Weeks</time_frame>
        <population>Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2409021 20 mg</title>
            <description>Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1c (HbA1c)</title>
          <description>LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.</description>
          <population>Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.</population>
          <units>percentage of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" lower_limit="-0.72" upper_limit="-0.58"/>
                    <measurement group_id="O2" value="-0.16" lower_limit="-0.23" upper_limit="-0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population Pharmacokinetics: Apparent Clearance of LY2409021</title>
        <description>Population pharmacokinetic parameter apparent clearance (CL/F) is the apparent volume of the body fluid cleared of the drug per unit of time and was estimated by modeling of LY2409021 plasma concentration data from all LY2409021 groups.</description>
        <time_frame>Days 7, 21, 42, 70, 77, 91, 112, 140; 15 minute Predose and Days 7 and 77: 1 hour Postdose.</time_frame>
        <population>Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2409021 20 mg</title>
            <description>Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods</description>
          </group>
        </group_list>
        <measure>
          <title>Population Pharmacokinetics: Apparent Clearance of LY2409021</title>
          <description>Population pharmacokinetic parameter apparent clearance (CL/F) is the apparent volume of the body fluid cleared of the drug per unit of time and was estimated by modeling of LY2409021 plasma concentration data from all LY2409021 groups.</description>
          <population>Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.</population>
          <units>Liter per hour (L/hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.406" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population Pharmacokinetics: Apparent Volume of Distribution of LY2409021</title>
        <description>Population pharmacokinetic parameter, apparent volume of distribution (V/F) is a theoretical volume that a drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma. Apparent volume of distribution (V/F) was estimated by modeling of LY2409021 plasma concentration data from all LY2409021 groups.</description>
        <time_frame>Days 7, 21, 42, 70, 77, 91, 112, 140; Predose and Days 7 and 77: 1 hour Postdose.</time_frame>
        <population>All randomized participants who received at least 1 one dose of study drug and had at least one measureable drug concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2409021 20 mg</title>
            <description>Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods</description>
          </group>
        </group_list>
        <measure>
          <title>Population Pharmacokinetics: Apparent Volume of Distribution of LY2409021</title>
          <description>Population pharmacokinetic parameter, apparent volume of distribution (V/F) is a theoretical volume that a drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma. Apparent volume of distribution (V/F) was estimated by modeling of LY2409021 plasma concentration data from all LY2409021 groups.</description>
          <population>All randomized participants who received at least 1 one dose of study drug and had at least one measureable drug concentration.</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LY2409021 20 mg</title>
          <description>AEs (Adverse Event) from Period 1 and 2 combined from LY2409021 20 mg administration</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>AEs from Period 1 and 2 combined from placebo administration.</description>
        </group>
        <group group_id="E3">
          <title>Wash-out</title>
          <description>All AEs included during wash-out period.</description>
        </group>
        <group group_id="E4">
          <title>Follow-up</title>
          <description>All AEs from follow-up period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="258"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="256"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="249"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="258"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Heart rate decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="258"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="258"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="258"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="256"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

